echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Study adds support for single-dose HPV vaccine regimen

    Study adds support for single-dose HPV vaccine regimen

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A single-dose human papillomavirus (HPV) vaccine was highly effective in a randomized controlled trial of 2,275 women in Kenya
    .
    The current standard for women is a three-dose regimen

    .

    The trial's lead investigator, Dr Ruanne Barnabas, said the results could help the World Health Organization achieve its goal of vaccinating 90 percent of 15-year-old girls against HPV by 2030
    .
    "A single dose has the same efficacy as multiple doses," she said

    .

    Currently, only 15% of women worldwide are vaccinated against HPV
    .

    At the time of the study, Barnabas was a professor of global health at the University of Washington School of Medicine in Seattle
    .
    She is now the director of the infectious disease department at Massachusetts General Hospital in Boston

    .

    Results from the "KEN-SHE" trial will be published Monday, April 11 in the New England Journal of Medicine's journal Evidence
    .

    "These findings are a game-changing finding that may substantially reduce the incidence of cervical cancer caused by HPV and make single-dose HPV vaccination a high-value, high-impact public health intervention for our It works," said
    Prof Sam Kariuki, acting director of the institute, who conducted the research at the Kenya Institute of Medical Research
    .

    The findings further support the adoption of a single-dose HPV vaccine, which may increase low-income and Accessibility in middle-income countries
    .

    "HPV vaccines are a powerful tool for reducing cervical cancer, but too many women and girls in low- and middle-income countries do not have access to them," said Dull
    .
    "KEN-SHE findings support the potential of single-dose HPV vaccination More and more evidence is provided

    .
    "

    Most sexually active men and women will get HPV at some point in their lives, and some will get it repeatedly
    .
    The peak time of infection in both women and men is shortly after being sexually active

    .

    While nine out of 10 HPV infections clear up on their own within two years, other infections lead to cancers of the reproductive system, primarily cervical cancer
    .
    HPV can also cause cancer of the cervix, vagina, vulva, penis, and oropharynx (larynx, tongue, and tonsils)

    .

    Worldwide, a woman dies from cervical cancer every two minutes
    .
    Most of these deaths occurred in Africa, which bears 80% of the cervical cancer burden

    .
    However, coverage has been low in areas with the highest burden of cervical cancer due to limited costs and vaccine availability

    .

    In the trial, women aged 15 to 20 were randomly assigned to one therapy and followed from December 2018 to June 2021
    .
    Eligible women need to be sexually active, have no more than 5 lifetime partners, be HIV-negative, and have no history of HPV vaccination

    .
    The majority of those who participated in the survey (57%) were between the ages of 15 and 17, and the majority reported having only one lifelong sexual partner (61%)

    .

    Participants were randomized into three treatment groups:

    • 760 people were vaccinated with bivalent vaccine covering both HPV strains (16/18), accounting for 70% of total cases

    • 758 people were vaccinated with invaluable vaccines covering seven HPV strains (16/18/31/33/45/52/58), accounting for 90% of total cases

    • 757 people were vaccinated against meningococcal meningitis
      .

    After 18 months, the bivalent vaccine was 97.
    5% effective against HPV 16/18 and the nonvalent vaccine was 97.
    5% effective against HPV 16/18

    .
    The invaluable vaccine was 89% effective against HPV 16/18/31/33/45/52/58

    .
    Even if women test positive for one strain of HPV, the vaccine protects them from other strains

    .

    The researchers say more studies need to be done to test the duration of the vaccine
    .

    "This trial brings new energy to the elimination of cervical cancer
    .
    It offers great hope to women living in countries such as Kenya, who bear the heavy burden of this disease," said the Clinical Research Centre, Kenya Medical Research Institute, Nairobi.
    Co-Principal Investigator and Senior Principal Clinical Research Scientist, Dr.
    Nelly Mugo

    .
    She is also an associate professor of global health studies at the University of Washington

    .

    One of the driving forces behind the trial, the researchers said, was the cervical cancer ward at Kenyatta National Hospital in Nairobi
    .
    They said they wanted the ward to be vacant

    .

    "I believe in my lifetime I will see cervical cancer eliminated," said Dr Maricianah Onono of the Kenya Institute of Medical Research
    .
    "So, let's do it - give every woman a chance!"

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.